• Profile
Close

Treatment adherence and support for people who inject drugs taking direct-acting antiviral therapy for hepatitis C infection

Journal of Viral Hepatitis Aug 18, 2019

Read P, Gilliver R, Kearley J, et al. - In this observational cohort study, researchers assessed treatment adherence when receiving direct-acting antivirals (DAAs) in a highly marginalized population at the Kirketon Road Centre, which is a community-based public health facility in Sydney, Australia. According to the findings, overall adherence was 86%; 92% of patients missed one or more doses. In 38%, they reported at least 90% adherence during planned duration, but that grew to 66% as a result of therapy continuing past the planned length. They concluded that those with multiple markers of marginalization may derive benefit from adherence support. Completion of therapy can be improved by extending therapy beyond the planned length of time. There is a need for strategies to enhance follow-up, especially posttreatment.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay